IG Group Holdings PLC (LON:IGG) Hold Rating Reaffirmed by Analysts at Shore Capital; Dicerna Pharmaceuticals (DRNA)’s Sentiment Is 3

IG Group Holdings PLC (LON:IGG) had its stock rating kept as Hold by stock analysts at Shore Capital. This was disclosed in analysts note on Thursday, 22 March.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally. The company has market cap of $576.17 million. The companyÂ’s preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases. It currently has negative earnings. It has a research collaboration and license agreements with Kyowa Hakko Kirin Co., Ltd.; City of Hope, an academic research and medical center; and Plant Bioscience Limited.

The stock decreased 0.09% or $0.01 during the last trading session, reaching $11.13. About 682,165 shares traded or 53.73% up from the average. Dicerna Pharmaceuticals, Inc. (DRNA) has declined 5.22% since March 22, 2017 and is downtrending. It has underperformed by 21.92% the S&P500.

Since January 1, 0001, it had 1 buy, and 0 insider sales for $2.00 million activity.

Ra Capital Management Llc holds 1.26% of its portfolio in Dicerna Pharmaceuticals, Inc. for 2.43 million shares. Ecor1 Capital Llc owns 957,992 shares or 0.73% of their US portfolio. Moreover, 683 Capital Management Llc has 0.46% invested in the company for 760,233 shares. The Vermont-based Birchview Capital Lp has invested 0.13% in the stock. Eventide Asset Management Llc, a Massachusetts-based fund reported 377,000 shares.

Analysts await Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) to report earnings on May, 14. They expect $-0.30 earnings per share, up 55.88% or $0.38 from last year’s $-0.68 per share. After $-0.90 actual earnings per share reported by Dicerna Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -66.67% EPS growth.

The stock increased 4.46% or GBX 36.5 during the last trading session, reaching GBX 854. About 733,909 shares traded. IG Group Holdings plc (LON:IGG) has 0.00% since March 22, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 7 analysts covering IG Group Holdings (LON:IGG), 2 have Buy rating, 0 Sell and 5 Hold. Therefore 29% are positive. IG Group Holdings has GBX 986 highest and GBX 520 lowest target. GBX 839.50’s average target is -1.70% below currents GBX 854 stock price. IG Group Holdings had 90 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Overweight” rating given on Tuesday, December 1 by Barclays Capital. The stock of IG Group Holdings plc (LON:IGG) earned “Overweight” rating by Barclays Capital on Monday, October 3. Liberum Capital maintained it with “Hold” rating and GBX 670 target in Monday, August 10 report. As per Tuesday, March 22, the company rating was maintained by Numis Securities. The stock of IG Group Holdings plc (LON:IGG) has “Hold” rating given on Wednesday, October 7 by Numis Securities. Barclays Capital maintained IG Group Holdings plc (LON:IGG) on Wednesday, September 23 with “Overweight” rating. On Thursday, October 29 the stock rating was maintained by Shore Capital with “Sell”. The firm has “Hold” rating by Shore Capital given on Tuesday, January 30. The company was maintained on Wednesday, November 11 by Barclays Capital. As per Thursday, December 8, the company rating was upgraded by Numis Securities.

IG Group Holdings plc engages in online trading business worldwide. The company has market cap of 3.14 billion GBP. The company, through its platform, offers contracts for difference, which are derivatives that enable clients to take the advantage of changes in an assetÂ’s price without owning the asset itself; and financial spread betting services. It has a 16.24 P/E ratio. It also operates North American Derivatives Exchange, a retail-oriented exchange, which enables investors to trade options on global financial markets.